

Curriculum vitae Paolo Bironzo

Personal details

Born in Vercelli (VC), Italy

Nationality: Italian

Email: paolo.bironzo@unito.it

Website: https://www.dep-oncology.unito.it/do/docenti.pl/Show?_id=pbironzo#tab-profilo

ORCID ID: 0000-0002-2784-5076; Scopus ID: 54909243900

Educations

- From 2017 to 2020: *PhD on Complex Systems for Life Sciences – University of Torino (TO), Italy*

- From 2012 to 2017: *Medical Oncology Specialization – University of Torino (TO), Italy. Evaluation: 70/70 cum laude*

- From 2004 to 2010: *Medical Doctor Degree – University of Torino (TO), Italy. Evaluation: 110/110*

- From 1999 to 2004: *High School Degree – Liceo Classico Isaac Newton, Chivasso (TO), Italy. Evaluation 100/100*

Professional experiences and current position

October 1st 2021 – Ongoing

Assistant Professor

University of Torino – Department of Oncology

October 1st 2018 – September 30th 2021

Research Fellow

University of Torino – Department of Oncology

August 1st 2017- September 30th 2018

Research Scholarship Holder

Prof. Silvia Novello and Prof Giorgio Vittorio Scagliotti- S.Luigi Gonzaga Hospital, Orbassano (TO)

July 2012 – July 2017

Residency in Medical Oncology

Prof. Giorgio Vittorio Scagliotti- S.Luigi Gonzaga Hospital, Orbassano (TO)

October 2011 – May 2012

Scholarship Holder

Research Scholarship Holder

Dr. Libero Ciuffreda - Oncologia Medica 1, Città della Salute e della Scienza, Molinette Hospital, Torino

Participation to Directive Boards of Scientific Societies and/or Institutions:

- Scientific Secretary for the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Malignant Pleural Mesothelioma (2017 – Ongoing)
- Chair for Pleural Mesothelioma at the European Organization for the Research and Treatment of Cancer (EORTC) Lung Cancer Group (2021-Ongoing)
- Member of the Pleural Mesothelioma Committee of the International Association of the Study of Lung Cancer (2019-2021)
- Member of the Communication Committee of the International Association of the Study of Lung Cancer (2017-2019)
- Member of Piemonte e Valle d'Aosta AIOM Regional Group (2015-2019; 2021-ongoing)
- Secretary of Piemonte e Valle d'Aosta AIOM Regional Group (2019-2021)
- Member of the Program Committee for the 2020 and 2022 World Conference on Lung Cancer (WCLC)
- “Giunta di Dipartimento” member at the Department of Oncology of the University of Torino (ongoing)
- “Commissione Ricerca” member at the Department of Oncology of the University of Torino (ongoing)

Honors

AIOM (Italian Association of Medical Oncology) research grant on Translational Research in Thoracic Oncology (2017).

Teaching activity:

Infermieristica Clinica in Area Medica - Canale A (MSL0266); corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo

Infermieristica Clinica in Area Medica - Canale B (MSL0266); corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo

Oncologia medica e cure palliative Canale A (MSL0266C); corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo

Oncologia medica e cure palliative Canale B (MSL0266C); corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo

Scuola di Specializzazione in Psicologia Clinica – Clinica Specialistica in Oncologia I

Scuola di Specializzazione in Psicologia Clinica – Supervisione su Lavoro Oncologico Ospedaliero

Research main topics

Thoracic Oncology: lung cancer, pleural mesothelioma, thymic epithelial tumors.

Main projects as PI:

- TANGIBLE: Alectinib in ALK+ advanced lung cancer patients: predictive biomarkers identification in real-life experience
- IMPACT: Innovative molecular platform for advanced lung cancer treatment
- TRAPPMESO: A translational & preclinical pipeline to investigate the efficacy of lurbinectedin and PARP inhibitors in mesothelioma, a proof of concept study

Bibliometry (2012-March 20th 2023) (www.scopus.com)

Citations 1847

Documents: 86

h-index: 19

Selected publications

- Contributor to the World Health Organization Thoracic Tumours Classification 5th Edition (WHO Classification of Tumours Editorial Board. Thoracic Tumours. Lyon (France):International Agency for Research on Cancer;2021)
- **Bironzo P**, Cani M, Jacobs F, et al Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy. Cancer. 2023 Mar 11.
- Rotolo R, Leuci V, Donini C, [...], **Bironzo P**, Sangiolo D. Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells. Clin Cancer Res. 2022
- Morfouace M, Novello S, Stevovic A, [...], **Bironzo P**, [...], Besse B. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTALung platform. Sci Rep. 2022 May 18;12(1):8342.
- Mezquita L, Preeshagul I, Auclin E, [...], **Bironzo P**, [...], Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer.2021;151:211-220.
- Anobile DP, **Bironzo P**, Picca F, et al. Evaluation of the preclinical efficacy of lurbinectedin in

- malignant pleural mesothelioma. *Cancers*.2021;13(10):2332
- Cortellini A, Di Maio M, Nigro O, [...], **Bironzo P**, [...], Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small-cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. *J Immunother Cancer*.2021;9(4):e002421
 - Siddiqui MA, Gollavilli PA, Ramesh V, [...], **Bironzo P**, [...], Ceppi P. Thymidylate synthase drives the phenotypes of epithelial-t-mesenchymal transition in non-small cell lung cancer. *Br J Cancer*.2020; 124(1):281-289
 - Tagliamento M, **Bironzo P**, Novello S. New emerging targets in cancer immunotherapy: the role of VISTA. *ESMO Open*.2020;4(suppl 3):e000683
 - Cortellini A, Tiseo M, Banna GL, [...], **Bironzo P**, [...], Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and PD-L1 expression of $\geq 50\%$. *Cancer Immunol Immunother*.2020
 - Reale ML, De Luca E, Lombardi P, [...], **Bironzo P**, [...], Scagliotti GV, Perrone F, Di Maio M. Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018. *Lung Cancer* 2020;139:47-54
 - Mazières J, Drilon A, Lusque A, [...], **Bironzo P**, [...], Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019;30(8):1321-28.
 - Milosevic V, Kopecka J, Salaroglio IC, [...], **Bironzo P**, [...], Riganti C. Wnt/IL-1 β /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. *Int J Cancer* 2020;146(19):192-207.
 - Salaroglio IC, Kopecka J, Napoli F, [...], **Bironzo P**, [...], Riganti C. Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma. *J Thorac Oncol* 2019;14(8):1458-71.
 - Villanova T, Gesmundo I, Audrito V, [...], **Bironzo P**, [...], Granata R. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. *Proc Natl Acad Sci U S A* 2019; 116:2226-31.
 - Bulik-Sullivan B, Busby J, Palmer CD, [...], **Bironzo P**, [...], Yelensky R. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. *Nat Biotechnol* 2018.
 - Marandino L, La Salvia A, Sonetto C, [...], **Bironzo P**, Di Maio M. Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. *Ann Oncol* 2018;29:2288-95.
 - Duruisseaux M, Martinize-Cardùs A, Calleja-Cervantes ME, [...], **Bironzo P**, [...], Esteller M. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter retrospective analysis. *Lancet Respir Med* 2018;6:771-81.
 - Lo Iacono M, Monica V, Righi L, [...], **Bironzo P**, [...], Scagliotti GV. “Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study”, *J Thorac Oncol*. 2015;10:492-9

Paolo Bironzo
Orbassano, March 20th 2023

Paolo Bironzo